Subanalysis of the AUGUSTUS trial
Comorbidity is a common feature of a modern patient. The combination of atrial fibrillation (AF) and various types of coronary artery disease is widespread in actual clinical practice. In such cases, additional pathophysiological mechanisms appear that worsen the clinical course and patient’s progno...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-09-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030817744519168 |
|---|---|
| author | T. V. Pavlova P. D. Duplyakova O. V. Shkaeva S. P. Krivova |
| author_facet | T. V. Pavlova P. D. Duplyakova O. V. Shkaeva S. P. Krivova |
| author_sort | T. V. Pavlova |
| collection | DOAJ |
| description | Comorbidity is a common feature of a modern patient. The combination of atrial fibrillation (AF) and various types of coronary artery disease is widespread in actual clinical practice. In such cases, additional pathophysiological mechanisms appear that worsen the clinical course and patient’s prognosis. The management of AF patients who have undergone acute coronary syndrome and/or percutaneous coronary intervention is a challenging problem, which can be solved by large-scale clinical trials. The AUGUSTUS randomized trial with a two-by-two factorial design proved that full-dose apixaban is superior in safety to the vitamin K antagonist warfarin, while not inferior in effectiveness. This pattern has been preserved in several important subanalysis on stent thrombosis, hospitalization rates, and conservative management of acute coronary syndrome. The obtained results are included in the novel European Society of Cardiology guidelines on AF. |
| format | Article |
| id | doaj-art-a077f8363e7b48958ea46bea33dc36e5 |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2020-09-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-a077f8363e7b48958ea46bea33dc36e52025-08-20T02:59:07Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-09-01253S10.15829/1560-4071-2020-41043056Subanalysis of the AUGUSTUS trialT. V. Pavlova0P. D. Duplyakova1O. V. Shkaeva2S. P. Krivova3Samara State Medical UniversitySamara State Medical UniversitySamara State Medical UniversitySamara State Medical UniversityComorbidity is a common feature of a modern patient. The combination of atrial fibrillation (AF) and various types of coronary artery disease is widespread in actual clinical practice. In such cases, additional pathophysiological mechanisms appear that worsen the clinical course and patient’s prognosis. The management of AF patients who have undergone acute coronary syndrome and/or percutaneous coronary intervention is a challenging problem, which can be solved by large-scale clinical trials. The AUGUSTUS randomized trial with a two-by-two factorial design proved that full-dose apixaban is superior in safety to the vitamin K antagonist warfarin, while not inferior in effectiveness. This pattern has been preserved in several important subanalysis on stent thrombosis, hospitalization rates, and conservative management of acute coronary syndrome. The obtained results are included in the novel European Society of Cardiology guidelines on AF.https://russjcardiol.elpub.ru/jour/article/view/4104atrial fibrillationacute coronary syndromepercutaneous coronary interventionapixabanaugustus |
| spellingShingle | T. V. Pavlova P. D. Duplyakova O. V. Shkaeva S. P. Krivova Subanalysis of the AUGUSTUS trial Российский кардиологический журнал atrial fibrillation acute coronary syndrome percutaneous coronary intervention apixaban augustus |
| title | Subanalysis of the AUGUSTUS trial |
| title_full | Subanalysis of the AUGUSTUS trial |
| title_fullStr | Subanalysis of the AUGUSTUS trial |
| title_full_unstemmed | Subanalysis of the AUGUSTUS trial |
| title_short | Subanalysis of the AUGUSTUS trial |
| title_sort | subanalysis of the augustus trial |
| topic | atrial fibrillation acute coronary syndrome percutaneous coronary intervention apixaban augustus |
| url | https://russjcardiol.elpub.ru/jour/article/view/4104 |
| work_keys_str_mv | AT tvpavlova subanalysisoftheaugustustrial AT pdduplyakova subanalysisoftheaugustustrial AT ovshkaeva subanalysisoftheaugustustrial AT spkrivova subanalysisoftheaugustustrial |